Generic drug from Kerlone
Therapeutic class: Cardiology and angiology
active ingredients: Betaxolol
laboratory: EG Labo
Divisible coated tablet
Box of 90
· Prophylaxis of stress angina attacks.
Dosage BETAXOLOL EG 20 mg Breakable film-coated tablet Box of 90
The usual dosage is 1 tablet at 20 mg per day in a single dose in both indications.
The plate -calendar identified on the days of the week will ensure better compliance by facilitating the patient's adherence to treatment.
Dosage in case of renal failure
Dosage should be adjusted to the status of renal function: up to a creatinine clearance of 20 ml per minute it is not necessary to change the dosage. However, clinical monitoring is recommended at the beginning of treatment until equilibration of blood levels (4 days on average).
In case of severe renal insufficiency (creatinine clearance <20 ml / min), the recommended initial dose is 10 mg / day (taken independently of the rhythm and schedule of extrarenal treatment sessions in the dialysis patient).
In patients with hepatic impairment, no change in dosage is necessary; however, clinical monitoring is desirable at the beginning of treatment.
· Asthma and chronic obstructive pulmonary disease, in their severe forms,
· Heart failure not controlled by treatment,
· Cardiogenic shock,
· Non-paired second and third degree atrioventricular blocks,
· Prinzmetal's angina (in pure forms and monotherapy),
· Sinus disease (including sinoatrial block),
· Bradycardia (<45 - 50 beats per minute),
· Raynaud's phenomenon and peripheral arterial disorders in their severe forms,
· Untreated pheochromocytoma,
· Hypersensitivity to betaxolol,
· History of anaphylactic reaction,
· Combination with floctafenine and sultopride (see section 4.5).
· This medication is generally not recommended in combination with amiodarone, bepridil, diltiazem, and verapamil (see section 4.5), and during breastfeeding.
Adverse effects Betaxolol EG
The most frequently reported:
· Cooling of the ends,
· Bradycardia, severe if any,
· Digestive disorders (gastralgia, nausea, vomiting),
Much less often:
· Slowing of atrioventricular conduction or intensification of an existing atrioventricular block,
· heart failure,
· Blood pressure drop,
· Raynaud's syndrome,
· Aggravation of an existing intermittent claudication,
· Various skin manifestations including psoriasiform rash or exacerbation of psoriasis (see Warnings and Precautions for Use section ),
· Dry eye,
In rare cases, it has been possible to observe the appearance of antinuclear antibodies which only exceptionally accompany clinical manifestations such as lupus syndrome and cede at the end of treatment.